Click Therapeutics Takes $50M From Boehringer to Commercialize Its Schizophrenia DTx — and Cuts 27% of Staff
The Series D hands Click full commercial rights to CT-155, which met its primary endpoint in the CONVOKE pivotal study. The simultaneous layoffs show how surviving DTx firms are restructuring around pharma-funded commercialization.
Boehringer Ingelheim has made a $50 million Series D strategic investment in Click Therapeutics, transferring full commercial responsibility and rights for CT-155 — an investigational prescription digital therapeutic for negative symptoms of schizophrenia — to Click. The company simultaneously cut 27% of its workforce as it pivots from R&D to commercial operations.
CT-155 met its primary endpoint in the CONVOKE pivotal study, with topline results in August 2025 and data presented that October. The product carries FDA Breakthrough Device designation; an FDA submission is pending, with no clearance yet as of July 2026. If cleared, it would be the first prescription digital therapeutic for schizophrenia negative symptoms.
The post-Pear playbook
Click already markets Rejoyn, developed with Otsuka — the first FDA-cleared prescription app for adjunctive treatment of major depressive disorder. The Boehringer deal, paired with deep cost cuts, illustrates the model that has emerged from the wreckage of Pear Therapeutics' 2023 collapse: digital therapeutics companies surviving not as independent consumer businesses but as clinical-grade software partners commercialized with pharma balance sheets.
With Medicare's digital mental health treatment codes now live and the FDA's TEMPO pilot opening an outcome-linked pathway, the reimbursement environment CT-155 will launch into is meaningfully better than the one that killed the category's first wave. Whether it is better enough is the question the whole DTx field is watching.
Reporting: Behavioral Health Business; Click Therapeutics press release via GlobeNewswire.
Source
Original reporting: Behavioral Health Business ↗